AKT1 and breast carcinoma: To confirm that this resistance is due to PI3K/AKT pathway hyperactivation, we treated the Irs4-transduced HER2+ breast cancer cell lines with a combination of Trastuzumab or Lapatinib and the PI3K-inhibitor GDC0941.